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Translational development of ABCB5+
dermal mesenchymal stem cells for therapeutic
induction of angiogenesis in non‑healing
diabetic foot ulcers
Andreas Kerstan1†, Kathrin Dieter2†, Elke Niebergall‑Roth3†, Sabrina Klingele3, Michael Jünger4,
Christoph Hasslacher5, Georg Daeschlein4,21, Lutz Stemler6, Ulrich Meyer‑Pannwitt7, Kristin Schubert8,
Gerhard Klausmann9, Titus Raab10, Matthias Goebeler1, Korinna Kraft2, Jasmina Esterlechner3,
Hannes M. Schröder2, Samar Sadeghi3, Seda Ballikaya3, Martin Gasser11, Ana M. Waaga‑Gasser11,12,
George F. Murphy13, Dennis P. Orgill14, Natasha Y. Frank15,16,17,18, Christoph Ganss2,3,
Karin Scharffetter‑Kochanek19, Markus H. Frank13,17,18,20† and Mark A. Kluth2,3*†   

Abstract
Background: While rapid healing of diabetic foot ulcers (DFUs) is highly desirable to avoid infections, amputa‑
tions and life-threatening complications, DFUs often respond poorly to standard treatment. GMP-manufactured
skin-derived ABCB5+ mesenchymal stem cells (MSCs) might provide a new adjunctive DFU treatment, based on
their remarkable skin wound homing and engraftment potential, their ability to adaptively respond to inflammatory
signals, and their wound healing-promoting efficacy in mouse wound models and human chronic venous ulcers.
Methods: The angiogenic potential of ABCB5+ MSCs was characterized with respect to angiogenic factor expression
at the mRNA and protein level, in vitro endothelial trans-differentiation and tube formation potential, and perfusionrestoring capacity in a mouse hindlimb ischemia model. Finally, the efficacy and safety of A
 BCB5+ MSCs for topical
adjunctive treatment of chronic, standard therapy-refractory, neuropathic plantar DFUs were assessed in an openlabel single-arm clinical trial.
Results: Hypoxic incubation of A
 BCB5+ MSCs led to posttranslational stabilization of the hypoxia-inducible tran‑
scription factor 1α (HIF-1α) and upregulation of HIF-1α mRNA levels. HIF-1α pathway activation was accompanied
by upregulation of vascular endothelial growth factor (VEGF) transcription and increase in VEGF protein secretion.
Upon culture in growth factor-supplemented medium, ABCB5+ MSCs expressed the endothelial-lineage marker
CD31, and after seeding on gel matrix, ABCB5+ MSCs demonstrated formation of capillary-like structures comparable
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with human umbilical vein endothelial cells. Intramuscularly injected A
 BCB5+ MSCs to mice with surgically induced
hindlimb ischemia accelerated perfusion recovery as measured by laser Doppler blood perfusion imaging and
enhanced capillary proliferation and vascularization in the ischemic muscles. Adjunctive topical application of ABCB5+
MSCs onto therapy-refractory DFUs elicited median wound surface area reductions from baseline of 59% (full analysis
set, n = 23), 64% (per-protocol set, n = 20) and 67% (subgroup of responders, n = 17) at week 12, while no treatmentrelated adverse events were observed.
Conclusions: The present observations identify GMP-manufactured ABCB5+ dermal MSCs as a potential, safe can‑
didate for adjunctive therapy of otherwise incurable DFUs and justify the conduct of a larger, randomized controlled
trial to validate the clinical efficacy.
Trial registration: ClinicalTrials.gov, NCT03267784, Registered 30 August 2017, https://clinicaltrials.gov/ct2/show/NCT03
267784
Keyword: ABCB5, Advanced-therapy medicinal product, Angiogenesis, Chronic wound, Diabetic foot ulcer,
Mesenchymal stem cells, Wound healing

Background
Diabetic foot ulcers (DFUs) are among the most common
and potentially serious complications of diabetes mellitus, with an estimated 19% to 34% of diabetes patients
developing a DFU during their lifetimes [1]. Around 40%
of patients who have developed a DFU die within 5 years
[2–4]. While a significant proportion of the mortality
rates can be attributed to fatal cardio-vascular complications of diabetes [5–7], the ulcer contributes independently to mortality due to inflammatory sequelae [4, 8,
9]. Specifically, more than half of DFUs become infected
[10], with roughly 20% to 50% of moderate-to-severe diabetic foot infections potentially leading to some grade of
lower extremity amputation [1, 11–14]. Many patients
who underwent a DFU-related amputation have a poor
quality of life and a high risk of premature death [15].
While rapid healing is highly desirable to avoid infections, amputations and life-threatening complications
[16–18], DFUs often respond poorly to standard treatment. Reported healing failure rates range from roughly
40% to 80% at 12 weeks and still from 15 to 70% at 1 year
of treatment (Additional file 1: Table S1). Current treatment guidelines advocate to consider adjunctive therapy options for DFUs that have not achieved a 50% area
reduction within 4 weeks [19–21] or failed to heal after
4–6 weeks [22] of standard wound care. There are an
increasing number of therapeutic efforts to speed the
healing of DFUs, and the literature surrounding their use
is evolving [23].
From a pathophysiologic perspective, dysfunctional
wound healing in diabetes is closely linked to insufficient angiogenesis [24], caused by a chronic inflammatory disposition in concert with impaired cellular
responses to tissue hypoxia [25–27]. A sustained, interleukin (IL)-1β-driven prevalence of pro-inflammatory
M1 macrophages associated with defective transition
to reparative, granulation-promoting M2 macrophages

[28–33] and an impaired activation of the hypoxiainducible transcription factor 1α (HIF-1α) pathway by
local fibroblasts and endothelial cells [34–36] leading
to deficient HIF-1α-dependent upregulation of multiple angiogenic factors including vascular endothelial
growth factor (VEGF) [34–38] ultimately result in a
decreased amount of nascent microvasculature [39, 40].
In the light of a complex pathophysiology, mesenchymal stem cells (MSCs), derived from various sources,
including adipose tissue, bone marrow, peripheral
blood and umbilical cord, have been extensively investigated and considered a promising approach to adjunctive DFU treatment [41–43], owing to their remarkable
ability to adaptively respond to signals associated with
tissue injury and inflammation by providing paracrine
signals which alter the wound environment toward a
pro-healing state or even directly participate in wound
regeneration [43, 44]. MSCs, among others particularly
adipose tissue-derived MSCs or stromal vascular fraction cells, have been safely and successfully used alone
or combined with dermal substitutes or autologous
growth factors such as platelet-rich plasma to treat
skin wounds and scars of various etiologies including
diabetic and vascular ulcers, burn wounds, post-traumatic wounds [45, 46]. Owing to a wide range of immunomodulatory capacities involving direct interactions
with immune cells as well as various paracrine pathways [47], they are considered attractive candidates for
the treatment of local and systemic inflammatory conditions including even COVID-19 [48]. However, most
of the investigated MSC therapies have not progressed
beyond early-stage clinical trials [49], and translation of
an MSC-based approach for the treatment of otherwise
non-healing DFUs that is readily (off the shelf ) available
and does not require an elaborate surgical procedure
into clinical practice has not yet been achieved.
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Recently, a skin-resident MSC population characterized by expression of ATP-binding cassette subfamily B member 5 (ABCB5) has been found severely
reduced in the dermis of diabetic db/db mice. This
might imply that the function of this cell population is
impaired under diabetic conditions, which, as a consequence, might favor poor wound healing in diabetes [50]. Conversely, ABCB5+ MSCs were shown to
respond to inflammatory milieus through multiple
cell contact-dependent and paracrine mechanisms
[51–53]. In a chronic wound model mimicking human
chronic venous ulcers, ABCB5+ MSCs shifted the M1
macrophage prevalence toward an M2 phenotype via
secretion of IL-1 receptor antagonist (IL-1RA) and
rescued impaired angiogenesis in the wound bed [53].
These effects were associated with an acceleration of
wound healing, which was also observed in human
chronic venous ulcers treated with ABCB5+ MSCs [54,
55]. Very recently, angiogenesis- and healing-promoting efficacy of A
 BCB5+ MSCs was demonstrated also
in a mouse diabetic wound model [50].
Dermal ABCB5+ MSCs cells can be easily accessed
from healthy human donors, expanded to a clinical
scale and delivered as a good manufacturing practice (GMP)-conforming advanced-therapy medicinal
product (ATMP) of proven purity, safety and tolerability [56, 57]. ABCB5+ MSCs display a spindle-like,
fibroblastoid cell morphology and express the minimal set of mesenchymal lineage markers CD73, CD90
and CD105, in addition to CD29, CD44, CD49e and
CD166, whereas no expression of the endothelial lineage marker CD31, the dendritic cell marker CD34, the
pan-hematopoietic lineage marker CD45, the monocyte/macrophage marker CD14 and the B lymphocyte
antigen CD20 was detectable by flow cytometry [51,
53]. A consistent and significantly increased potential
for adipogenic, osteogenic, and chondrogenic lineage
differentiation delineates human ABCB5+ MSCs from
donor-matched ABCB5– dermal fibroblasts [53]. Aiming at developing ABCB5+ MSCs for the treatment of
human DFUs, we here characterize their angiogenic
potential with respect to angiogenic factor expression
at the mRNA and protein level, in vitro endothelial
trans-differentiation and tube formation potential, and
in vivo perfusion-restoring capacity. Building upon
these results in conjunction with the existing evidence
on the cells’ anti-inflammatory potential we have
established three potency assays in order to deliver
human skin-derived ABCB5+ MSCs as an ATMP with
standardized biological activity. Finally, this product
was tested in a clinical trial in patients suffering from
non-healing, standard treatment-refractory DFUs.
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Methods

Expansion and isolation of human ABCB5+ MSCs

Human ABCB5+ MSCs were derived from skin samples obtained from patients undergoing abdominoplasties or other surgical interventions that provide
left-over skin tissue after informed written consent was
obtained. Cell production was carried out in an EUGMP grade A cabinet in a grade B clean room under
laminar air flow following a validated GMP-conforming
protocol as described previously [56]. In brief, after
enzymatic digestion of the skin tissue, cells were centrifuged and expanded as unsegregated culture by serial
passaging upon adherence selection in an in-house
MSC-favoring medium (Ham’s F-10 supplemented with
fetal calf serum, L-glutamine, fibroblast growth factor 2
(FGF-2), HEPES, hydrocortisone, insulin, glucose, and
phorbol myristate acetate). A
 BCB5+ cells were isolated by antibody-coupled magnetic bead sorting using
a mouse anti-human ABCB5 monoclonal antibody
directed against the extracellular loop 3 of the ABCB5
molecule [58] (Maine Biotechnology Services, Portland,
Maine; GMP purification: Bibitec, Bielefeld, Germany),
cryo-preserved in CryoStor® CS10 freeze medium
(BioLife Solution, Bothell, WA) containing 10% dimethyl sulfoxide and stored in the vapor phase of liquid
nitrogen.
Hypoxia studies
Induction of cell hypoxia

ABCB5+ MSCs (3 × 105) were seeded in 750 µl MSCfavoring medium in a culture dish and placed in a
hypoxia chamber, which was flushed for 5 min with
nitrogen-enriched gas (1% O2, 4% CO2, 95% N2; Air
Liquide, Düsseldorf, Germany) at a rate of 20–25 l/
min. During cultivation for up to 48 h, the chamber was
flushed again after 1 h and 24 h.
ABCB5+ MSCs were centrifuged (Cytospin™; Thermo
Fisher, Dreieich, Germany) onto coverslips, fixed with
4% paraformaldehyde solution, permeabilized with 1%
Triton™ X-100 (Sigma-Aldrich, Taufkirchen, Germany)
in phosphate-buffered saline, blocked with 0.5% bovine
serum albumin in phosphate-buffered saline, and
stained for HIF-1α (for antibodies see Additional file 1:
Table S2). Nuclei were counterstained with 4’,6 diamidino-2 phenylindole (DAPI).
HIF‑1α staining

Total RNA was isolated using the RNeasy® Micro
Kit (Qiagen, Hilden, Germany) and reverse-transcribed into cDNA using the Applied Biosystems™
Quantitative real‑time polymerase chain reaction (qPCR)
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High-Capacity cDNA Reverse Transcription Kit
(Thermo Fisher) and the Applied Biosystems™ SYBR
Green Mastermix (Thermo Fisher) in a four-step process run in a Mastercycler® Personal thermocycler
(Eppendorf, Hamburg, Germany). PCR reactions
were run in triplicate in an Applied Biosystems™ StepOne RealTime™ PCR System (Thermo Fisher). Primer
sequences are provided in Additional file 1: Table S3.
Actin served as housekeeping gene. Primer quality and
integrity of the amplified product was confirmed by
melting curve analysis. Identity of the PCR products
was confirmed by agarose gel electrophoresis. Relative
quantification of transcript levels was determined using
the 2−ΔΔCt algorithm.
Enzyme‑linked immunosorbent assay (ELISA)

VEGF concentration in the cell culture supernatant was
measured using the Invitrogen VEGF Human ELISA
Kit (Thermo Fisher), according to the manufacturer’s
instructions. Assays were run in triplicate.
Trans‑differentiation studies
Angiogenic trans‑differentiation assay

ABCB5+ MSCs (1 × 106) were seeded in 24-well culture
plates and cultured for up to 96 h in culture medium
supplemented with 200 ng/ml recombinant human (rh)
VEGF (Sigma-Aldrich), 1000 ng/ml rhFGF-2 (CellGenix,
Freiburg, Germany) and 1000 ng/ml rh platelet-derived
growth factor-BB (PDGF-BB; R&D Systems, Wiesbaden,
Germany). Trans-differentiation and proliferation activity were assessed by CD31 and Ki67 staining, respectively
(for antibodies see Additional file 1: Table S2). Nuclei
were counterstained with DAPI. All experiments were
performed in triplicates. Human umbilical vein endothelial cells (HUVECs; 5 × 105; Thermo Fisher) served as
positive control.
Tube formation assay

ABCB5+ MSCs (1 × 105/ml or 1.5 × 105/ml) and
HUVECs (0.5 × 105/ml or 1 × 105/ml) were seeded on
Geltrex™ (Thermo Fisher)-coated culture plates and
incubated at 37 °C for 19–22 h (ABCB5+ MSCs) and
16–18 h (HUVECs). For examination of cell viability, cells
were stained with calcein acetoxymethylester (Thermo
Fisher; 1:10,000, 30 min, 37 °C). Tube formation and
calcein fluorescence were evaluated microscopically
(EVOS™ FLoid™ cell imaging station).
Animal studies
Hindlimb ischemia (HLI) induction and post‑surgical care

Male OF1 mice (Charles River Laboratories, SaintGermain-Nuelles, France) were anesthetized with 2%
isoflurane in 100% oxygen, and the inner faces of both
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hindlimbs were carefully shaved. After local disinfection, an about 1-cm skin incision was made on the left
hindlimb from the inguinal region to the bifurcation
region of the femoral artery into the saphenous and popliteal artery. The femoral artery and vein were dissected
from the nerve. The femoral artery/vein block was ligated
proximally by two 8–0 ties placed just distally from the
superficial epigastric artery, and distally by two 8–0 ties
placed just proximally from the bifurcation of the femoral artery into the saphenous and the popliteal artery.
After cutting the femoral artery/vein block between the
two proximal and between the two distal ties, the femoral
artery/vein block was removed. When necessary, major
branches such as the lateral circumflex femoral artery
were ligated to avoid bleeding.
Thereafter, subcutaneous tissue and skin were closed
with non-resorbable sutures or clamped with titanium
micro clips (WDT, Garbsen, Germany). Postoperative
care included pain management by injection of buprenorphine (Buprenovet, Bayer; 0.1 mg/kg) once directly after
surgery or flunixin meglumine (2.5 mg/kg twice daily)
during 3 days and daily local wound care with an antiseptic healing cream (Dermaflon, Pfizer).
Injection of ABCB5+ MSCs

On the day after surgery, mice were anesthetized with
isoflurane to receive intramuscular injections at the
ischemic limb of human ABCB5+ MSCs suspended in
Ringer’s lactate solution containing 2.5% human serum
albumin and 0.4% glucose at concentrations between
1 × 106 and 1 × 108 cells/ml, as required. Cell doses, injection volumes and sites are given in the Results section.
Blood perfusion measurement

Animals were anesthetized with isoflurane and placed on
a warming platform in a supine position for imaging at
the internal face of the thighs. Hindlimb blood flow was
measured before and immediately after surgery (day 1)
and on days 3, 5, 7, 14, 21 and 28 by real-time laser Doppler blood perfusion imaging (LDPI; PeriCam PSI, Perimed Instruments). The scanned area covered an ellipse
framing internal face of the thigh. Blood perfusion was
expressed as the ratio between LDPI values in the left
(ischemic) and right (non-ischemic) limb.
Histopathology

After sacrifice, the left, ischemic thigh and gastrocnemius
muscles were preserved in 10% neutral buffered formalin solution, embedded in paraffin wax, cut to 2–4 µm
thickness, stained with hematoxylin and eosin, and
inspected by conventional light microscopy. Histopathological findings were quantified according to the scoring
system for local cellular and tissue responses described
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by ISO 10993-6:2007 [59], evaluating the criteria polymorphonuclear cells, lymphocytes, plasma cells, macrophages, giant cells, myofiber degeneration, myofiber
regeneration, necrosis, neovascularization, fibrosis, fatty
infiltrates and mineralization. Neovascularization was
semi-quantitatively quantified as 0 = none, 1 = minimal
capillary proliferation, focal, 1–3 buds, 2 = groups of
4–7 capillaries with supporting fibroblastic structures,
3 = broad band, and 4 = extensive band of capillaries with
supporting fibroblastic structures.
Immunohistochemistry

After sacrifice, left, ischemic thigh muscles were preserved in 10% neutral buffered formalin solution, which
was replaced after 24–48 h with 70% ethanol. Immunohistochemical staining for CD31 was performed using
rabbit anti-human/mouse CD31 (ab28364, Abcam; dilution 1:50) and dextran polymer-horseradish peroxidaselabeled anti-rabbit IgG (DAKO EnVision® + , K4010,
Agilent) for detection. CD31 expression was semi-quantitatively quantified as 0 = none, 1 = minimal, 2 = slight,
and 3 = moderate by two independent investigators who
were blinded to the treatment.
Statistics

One-way ANOVA followed by Dunnett’s test was used to
compare LDPI ratios versus baseline and neovascularization and CD 31 expression in the cell-treated groups versus control.
Clinical trial
Patients

Adults (18–85 years) with diabetes mellitus type 2
(hemoglobin A1c < 11%) were eligible if they had a neuropathic diabetic plantar foot ulcer (Wagner grade 1 or 2,
1–50 cm2), confirmed by vibration sense testing (128-Hz
Rydel-Seiffer tuning fork) without the presence of significant arterial disease (ankle-brachial index ≥ 0.7 or transcutaneous oxygen pressure > 40 mmHg or as per Doppler
ultrasonography).
Main exclusion criteria were acute Charcot foot, active
osteomyelitis, treatment-requiring ulcer infection, adjacent or chronic skin disorders, skin malignancies, acute
or untreated deep vein thrombosis, need for hemodialysis, surgical procedures within 2 months and use of active
wound care agents within 2 weeks prior to treatment,
and current use of systemic immunosuppressants, cytotoxics or glucocorticoids.
Trial design

The study was a national, multicenter (eight sites in Germany), open-label, single-arm, phase I/IIa trial comprising three periods: standard-of-care screening (≥ 6 weeks),
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treatment and efficacy follow-up (weeks 1–12), and safety
follow-up period (until end of month 12). The trial was
performed in accordance with the Declaration of Helsinki and local regulations and approved by the ethical
committees of all participating study sites. Patients gave
written informed consent prior to trial participation.
Interventions

Treatment consisted of up to two topical applications of
2 × 106 allogeneic ABCB5+ MSCs (suspended in Ringer’s
lactate solution containing 2.5% human serum albumin
and 0.4% glucose [56]) per cm2 wound area on day 0 and
at week 6. The cells were manufactured as a GMP-conforming standardized ATMP (for main product release
data see Additional file 1: Table S4). Originally, only
one cell application was planned. The second application was amended to the protocol only after data from
a first-in-human trial on chronic venous ulcers [54] suggested that a second cell dose at 6 weeks after the first
cell dose might provide additional benefit for chronic
wound healing. Cell application could be preceded by an
optional wound debridement at the investigator’s discretion followed by waiting until the bleeding had entirely
stopped. For cell application, a suspension containing
1 × 107 ABCB5+ MSCs/ml was applied onto the wound
surface, delivering 2 × 106 ABCB5+ MSCs/cm2 wound
surface area. Thereafter, the cells were allowed to settle
for 15–30 min, optionally fixed in place with fibrin gel
(Tisseel®; Baxter, Unterschleißheim, Germany), and then
the wound was covered with a waterproof film dressing
(Tegaderm™; 3 M, Neuss, Germany). On the following
day (≥ 12 h after cell application), the film dressing was
replaced by a microbe-binding dressing (Cutimed® Sorbact® tamponade or compress; BSN, Hamburg, Germany),
which was changed again 1–2 days later. Additionally,
patients received standard care until week 12 including
glycemic control, ulcer debridement, appropriate wound
dressings (i.e., microbe-binding tamponade of cavities
and exudate-absorbent foam dressing for coverage), and
antibiotics if required. All patients had to use offloading
devices including cast devices or individually fitted therapeutic footwear [19, 60, 61].
Outcome measures

Primary efficacy endpoint was percent wound surface
area reduction at week 12 or last available post-baseline measurement. Secondary efficacy endpoints were
percent and absolute wound surface area reduction
at predefined visits, proportion of patients achieving
complete and 30% wound closure, time to complete
and to 30% wound closure, granulation, epithelialization, wound exudation, time to amputation at the target leg, pain and life quality. Safety outcome measures
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included adverse events (during the whole study
period) and vital signs, changes in physical examination findings and time to amputation of the target leg
(during efficacy follow-up).
Outcome determination

Wound surface area determination followed a multistep
approach combining computerized evaluation (PictZar®
planimetry software; BioVisual, Elmwood Park, NJ, USA;
98% accuracy, 94% inter-rater reliability, 98% intra-rater
reliability according to a validation and reliability study
[62]) of standardized photographs and depth measurements using a wound measuring probe, to account for
the typical three-dimensional shape of DFU wounds, i.e.,
consisting of wound floor, side wall and, occasionally,
not visible tunneling or undermining areas. For details
of the measuring and calculation algorithm see Additional file 2: Methods S1. Formation of granulation and
epithelial tissue was estimated by the investigator in %
of wound area from standardized wound photographs.
Wound exudation was rated by the investigator as low
(dry), moderate (moist), and high (wet) according to the
criteria defined by the World Union of Wound Healing
Societies [63]. Pain was rated by the patient using a 0–10point numerical rating scale with 0 = no and 10 = worst
imaginable pain. Quality of life was assessed using the
participant-reported Short Form (36) Health Survey
(SF-36) and Dermatology Life Quality Index (DLQI)
questionnaires.
Sample size

Enrolment followed a Simon optimal two-stage design
with responders defined as patients presenting with
at least 30% wound surface area reduction at week 12.
The sample size required to achieve 80% power at
5% significance level was calculated using PASS 13
software (NCSS, East Kaysville, UT, USA) to be
37 patients. This enabled the option to terminate the
trial if ≤ 6 or ≥ 14 of the first 18 treated patients were
responders. As in an interim analysis 12 of 18 patients
emerged as responders, recruitment was continued. However, by force of the emerging COVID-19
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pandemic, the trial was prematurely completed. At
that time, 23 patients had been treated.
Statistical analysis

Safety assessments were performed on the safety analysis
set, which included all patients who received at least one
cell dose. Efficacy assessments were performed on the full
analysis set (FAS), which included all patients of the safety
analysis set who underwent wound surface area assessments at baseline and at least one post-baseline visit, and
on the per-protocol set (PP), which included all patients of
the FAS who had no major protocol deviations.
If not otherwise stated, normally (D’Agostino–Pearson
normality test) distributed parameters are presented as
mean ± standard deviation, and non-normally distributed
parameters as median and interquartile range (IQR). Statistical significance of percent wound surface area changes
from baseline was tested against the null hypothesis
(median change = 0) using a two-sided Wilcoxon signed
rank test. Time to complete wound closure, time to 30%
wound surface area reduction and time to amputation
at the target leg were analyzed using the Kaplan–Meier
method.

Results
Hypoxia studies
Hypoxia‑induced HIF‑1α activation in ABCB5+ MSCs

Prior to hypoxic incubation, HIF-1α protein was mainly
detectable in the cytoplasm. During hypoxic incubation,
cytoplasmic HIF-1α fluorescence decreased while nuclear
HIF-1α fluorescence increased. At 24 h of hypoxia, HIF-1α
was mainly detectable in the nuclei, indicating that nuclear
translocation has occurred (Fig. 1A). In contrast, on the
transcriptional level, HIF-1α mRNA expression peaked
after 1 h of hypoxic culture and decreased thereafter, dropping down to roughly 10% of the baseline value at 48 h
(Fig. 1B).
Hypoxia‑induced VEGF mRNA expression and protein
secretion in ABCB5+ MSCs

During hypoxia, VEGF mRNA expression increased about
fourfold from baseline at 5 h, remaining on that level during
48 h (Fig. 1C). VEGF protein secretion steadily increased
during 48 h of hypoxic culture (Fig. 1D).

(See figure on next page.)
 BCB5+ MSCs
Fig. 1 HIF-1α and VEGF expression by ABCB5+ MSCs during hypoxic culture. A Representative immunofluorescence staining of A
revealing nuclear translocation of HIF-1α at 24 h. Nuclei were counterstained with DAPI. Scale bars: 20 µm. B HIF-1α mRNA expression by A
 BCB5+
MSCs from two donors, shown as fold expression from baseline (normoxic conditions, 0 h). Data are means + SD of three replicates. C VEGF mRNA
expression by ABCB5+ MSCs, shown as fold expression from baseline (normoxic conditions, 0 h). Data are means + SD of three donors. D VEGF
protein secretion by ABCB5+ MSCS, measured as VEGF protein concentration in culture supernatant. Data are means + SD of three replicates from a
representative donor
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Fig. 1 (See legend on previous page.)
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Angiogenic potency assay

The VEGF ELISA after hypoxic culture was used as a surrogate potency assay to predict the pro-angiogenic bioactivity of GMP-compliantly produced A
 BCB5+ MSCs for use
in clinical trials. Since VEGF secretion was highest at 48 h
of hypoxic culture (Fig. 1D), the 48-h time point was set as
temporal endpoint for potency testing. In validation studies (not shown), a VEGF concentration in the supernatant
of ≥ 46.9 pg/ml, corresponding to an optical density threshold < 3.0 in the serial standard dilution of the ELISA kit, was
validated to reliably enable qualitative detection and, therefore, defined as acceptance criterion for cell batch release.
For the potency data of the cell batches used in the present
clinical trial see Additional file 1: Table S4.
Trans‑differentiation studies
Growth factor‑stimulated endothelial trans‑differentiation

After 96-h culture in medium supplemented with 200 ng/
ml VEGF, 1000 ng/ml FGF-2 and 1000 ng/ml PDGFBB, ABCB5+ MSCs underwent endothelial trans-differentiation as revealed by CD31 expression (Fig. 2A–C).
Trans-differentiation was accompanied by an enhanced
proliferative activity as evidenced by Ki67 staining
(Fig. 2D–F).
After 18–20-h cultivation on Geltrex™ gel matrix,
ABCB5+ MSCs formed capillary-like structures similar
to HUVECs that were used as positive control. The tubular structures stained positive for calcein, demonstrating
viability (defined as metabolic activity measured by conversion of calcein acetoxymethylester to calcein) of the
tube-forming cells (Fig. 3).
Tube formation on gel matrix

Trans‑differentiation potency assay

The tube formation assay was used as a surrogate
potency assay to predict the trans-differentiation capacity of GMP-compliantly produced ABCB5+ MSCs for use
in clinical trials. For grading, tube formation of ABCB5+
MSCs was semi-quantitatively classified into six categories ranging from 1 = tubular branches of several cells
forming a defined network-like structure to 6 = no tubular branches visible (for a more detailed description of all
categories see Additional file 1: Table S4, with ≤ 3 in at
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least one of the two seeded cell concentrations (1 × 105/
ml and 1.5 × 105/ml) being considered as successful angiogenic differentiation. For the potency data of the cell
batches used in the present clinical trial see Additional
file 1: Table S4.
Animal studies
Blood flow recovery in surgically induced HLI

Mice (n = 10 per group) received 5 × 106 ABCB5+ MSCs/
animal or vehicle only by intramuscular injection (200 µl
injection volume split over 4 injection sites at the internal face of the thigh) at 24 h after HLI induction. During the study, a certain mortality (day 3, 10%; day 5, 20%;
day 7, 25%) was observed, which did not differ between
groups. Blood perfusion measured by LDPI (Fig. 4A) and
expressed as ratio between LDPI values in the ischemic
and the non-ischemic limb (Fig. 4B; Additional file 1:
Table S5) significantly decreased immediately after surgery in both treatment groups. During the following days
the LDPI ratio gradually recovered, reaching baseline
levels on day 5 in the MSC-treated group as compared
to day 14 in the vehicle-treated group, with the most
pronounced difference in LDPI ratio between groups
occurring between days 5 and 7 (Fig. 4B; Additional
file 1: Table S5). These results confirmed the observations of a preceding pilot study in OF1 mice with surgically induced HLI showing blood flow recovery within
5 days after injection of A
 BCB5+ MSCs but not of vehicle
(Additional file 3: Figure S1).
CD31 expression in surgically induced HLI

Mice (n = 10 per group) received 5 × 105, 1 × 106 or
5 × 106 ABCB5+ MSCs/animal or vehicle by intramuscular injection (200 µl injection volume split over
4 injection sites at the internal face of the thigh) at 24 h
post-HLI induction. At day 6, semiquantitative immunohistochemical evaluation revealed a significant increase
in mean CD31 expression in the left thigh muscles of
mice treated with the two higher cell doses as compared
to the vehicle group (Fig. 4C, Additional file 1: Table S6).
In a validation study on OF1 mouse and human skin sections, the CD31 antibody showed cytoplasmic staining of
endothelium in both species (Additional file 3: Figure S2).
Thus, the staining protocol was suitable to picture the

(See figure on next page.)
Fig. 2 Endothelial trans-differentiation of A
 BCB5+ MSCs. A Co-stimulation for 96 h with 200 ng/ml VEGF, 1000 ng/ml FGF-2 and 1000 ng/ml
PDGF-BB elicited angiogenic trans-differentiation of A
 BCB5+ MSCs as revealed by CD31-positive (red) staining. B ABCB5+ MSCs cultured without
growth factor supplementation served as negative control. C HUVECs served as positive control. D–F Proliferative activity of A
 BCB5+ MSCs
+
stimulated to undergo endothelial trans-differentiation. D ABCB5 MSCs were stimulated for 96 h with 200 ng/ml VEGF, 1000 ng/ml FGF-2 and
1000 ng/ml PDGF-BB. Proliferative activity was assessed by Ki67 staining (red). E ABCB5+ MSCs cultured without growth factor supplementation
served as negative control. F HUVECs served as positive control. Nuclei were counterstained with DAPI (blue). Representative images of three
independent experiments
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A

10 X

100 µm

Calcein-AM

100 µm

Calcein-AM

100 µm

B

10 X

100 µm

Fig. 3 Tube formation assays. A Human ABCB5+ MSCs and B HUVECs were cultured for 18–20 h on Geltrex™ matrix. Calcein staining (green)
demonstrates viability (i.e., metabolic activity) of tubular structure-forming cells

formation of capillaries generated from both mice resident cells and administered human MSCs.
Neovascularization in surgically induced HLI

Mice received 1 × 105, 5 × 106 or 1 × 107 ABCB5+
MSCs/animal (n = 7 per group) or vehicle (n = 6) by
intramuscular injection (100 µl injection volume split
over 5 injection sites at the quadriceps, semitendinosus
and gastrocnemius muscles) at 24 h post-HLI induction. At day 6, inflammatory and degenerative myofiber
reactions were observed in all groups. The mean summary score was lower in the mice treated with the two
lower cell doses and higher in the mice treated with the

highest cell dose as compared with the control group;
however, the differences were not statistically significant (Fig. 4D, E). In contrast, semiquantitative histological evaluation revealed a significant increase in the
mean neovascularization score in the left (ischemic)
gastrocnemius muscles of mice treated with the highest
cell dose as compared to the vehicle group (Fig. 4D, F).
Clinical trial
Progress of the study

Patients were enrolled between November 2017 and
January 2020. Forced by the COVID-19 pandemic, which
was associated with critical issues including staffing

(See figure on next page.)
Fig. 4 Blood flow recovery and neovascularization following surgically induced HLI in OF1 mice. A Representative LDPI acquisition before and
immediately after HLI induction, illustrating the experimental setup. Scanned areas are marked by ellipses; the warmest color (intense red)
represents 200 perfusion units. Graphs show mean perfusion unit during 1 min in the non-ischemic (blue) and ischemic (red) thigh. B LPDI ratio
between the ischemic and the non-ischemic limb in mice treated with 5 × 106 ABCB5+ MSCs or vehicle. Means with SD of n = 10 (day 1), n = 9
(day 3), n = 8 (day 5; days 7–21 MSCs) and n = 7 (days 7–21 vehicle) animals. C–F Immunohistochemical and histopathological evaluation of the
ischemic hindlimb muscles at 6 days after HLI induction in mice treated with A
 BCB5+ MSCs or vehicle injected into the ischemic limb 24 h after
surgery. C CD31 expression in the thigh muscles, presented as mean (SD) IHC score, with 0 = none, 1 = minimal, 2 = slight, and 3 = moderate, of
n = 12 animals. D Representative H&E sections of the gastrocnemius muscle from a vehicle- and an MSC-treated mouse, showing inflammatory and
degenerative lesions in both mice and increased neovascularization in the MSC-treated mouse. Scale bars: 50 µm. E Degenerative and inflammatory
processes in the gastrocnemius muscle, presented as mean (SD) summary score according to ISO 10993–6:2007 of n = 6 (vehicle) and n = 7 (MSCs)
animals. F Neovascularization in the gastrocnemius muscle, presented as mean (SD) score, with 0 = none, 1 = 1–3 focal buds, 2 = groups of 4–7
capillaries with supporting fibroblastic structures, 3 = broad band and 4 = extensive band of capillaries with supporting fibroblastic structures, of
n = 6 (vehicle) and n = 7 (MSCs) animals. *p < 0.05, **p < 0.01, ***p < 0.001 versus baseline (B) or vehicle (C, E, F); one-way ANOVA with Dunnett’s post
hoc test
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shortages, impairments of supply chains and increased
infection risk for the elderly and/or comorbid study
patients, recruitment and treatment were discontinued
as of April 2020, and the trial was prematurely completed
as of end of June 2020 after consultation with the ethics
committee and the regulatory authority. At that time, all
treated patients had completed the efficacy follow-up.
Patients who had entered the safety follow-up period but
were not scheduled for a safety visit in June 2020 were
subjected to a supplementary end-of-study visit (Fig. 5A,
B).
Patients

Totally 63 patients were screened, of which 23 patients
(20 men, 3 women) were treated (Fig. 5B). During the
screening period, which ranged from 42 to 68 days (one
outlier: 118 days; median: 49 days), changes in wound
surface area ranged from 56% decrease to 175% enlargement (median change 0%) (Fig. 5C). Baseline characteristics of the treated patients are listed in Table 1.
Of the 23 treated patients, 7 patients received only one
cell application: 3 patients because they had been enrolled
under earlier protocol versions before the second application was amended to the protocol, two patients because
their wounds were already closed at the week-6 visit, one
patient due to a (not treatment-related) foot fracture, and
one patient due to COVID-19 pandemic-related treatment discontinuation. One patient was lost to follow-up
after the month-9 safety visit (Fig. 1B). Three patients
had major protocol deviations: use of prohibited medication (active wound care agent), delayed week-12 visit,
improper off-loading. These patients were analyzed in
the FAS (N = 23) but excluded from the PP (N = 20).
Efficacy outcomes

The wound healing progress of three representative
responders is illustrated in Fig. 6. The primary efficacy outcome, median wound surface area reduction
from baseline at week 12, was 59% (IQR: 27–96%, FAS)
and 64% (IQR: 46–96%, PP) (p < 0.001 in both sets)
(Fig. 7A–C).
A summary of the secondary efficacy outcomes is given
in Table 2.
Absolute wound surface area reduction was most pronounced during the first 2 weeks after the first and second MSC application, i.e., from day 0 till week 2 and
from week 6 till week 8, respectively (Additional file 1:
Table S7).
Complete wound closure was achieved in 6 patients
(26% for FAS and 30% for PP; Additional file 1: Table S8).
Since less than half of patients experienced complete
wound closure during the efficacy follow up, the median
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time to complete wound closure could not be determined
(Fig. 7D).
Wound surface area reduction by at least 30% at
week 12 was observed in 17 patients (74% for FAS
and 85% for PP) (Additional file 1: Table S8). These
patients were considered responders. The median time
to first 30% wound surface area reduction was 27 days
(95%-CI: 14; 30; FAS) and 22 days (95%-CI: 14; 30; PP)
(Fig. 7E).
Due to the nature of DFU morphology, formation
of granulation and epithelial tissue was not reliably
evaluable.
Most patients demonstrated low or moderate wound
exudation. The proportions of patients with low, moderate or high exudation varied slightly over time with
a few more patients having low exudation at week 12
than on day 0 (52% vs. 44% and 50% vs. 35% for FAS
and PP, respectively) (Additional file 1: Table S9).
An amputation at the target leg until week 12 was
reported in one patient. The reason was a fracture of
the little toe, which the investigator judged as unrelated to the cell therapy. Since only one patient experienced an amputation during the efficacy follow up, the
median time to amputation could not be calculated.
Median pain score was low during the whole 12-week
follow-up period (Additional file 1: Table S10). The
SF-36 subscale scores remained virtually unchanged,
while the median DLQI slightly improved from 6
(1–12) at day 0 to 4 (0–10) at week 12 (Additional file 1:
Table S11).
Post hoc analyses

Wound size analyses were additionally performed on
the subgroup of responders, i.e., all patients who presented with ≥ 30% wound surface area reductions from
baseline at week 12. Baseline patient characteristics, percent change of wound surface area during screening and
baseline wound size did not differ between the responders and the non-responders (Fig. 8A, B). All except three
responders had achieved first 30% wound surface area
reduction within 30 days; median time to first 30% wound
surface area reduction was 16 days (Fig. 7E). At week 12,
median wound surface area reduction from baseline was
67% (55%–98%) (Fig. 7C), and in 6 of 17 (35%) responders the wound had fully closed.
Since in the trial protocol no threshold values had
been specified to exclude patients from study treatment
based on their wound surface area changes during the
screening period, a Spearman’s rank correlation analysis
was performed to test whether there was an association
between wound surface area reduction during the screening period and during the efficacy follow-up period. A
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Fig. 5 Trial design, study patients and wound surface area during screening. A Schematic representation of the trial design. aOnly patients who
did not reach month-12 visit before 30 June 2020 and were not scheduled for a planned safety follow-up visit in June 2020 were subjected to an
end-of-study visit. B Study patient flow chart. EoS visit, end-of-study visit [see (a)]. C Percent reduction of wound surface area during a ≥ 6-week
screening period (median 49 days, range 42–68 days; except for one outlier, whose screening period lasted 118 days, denoted by an asterisk). Error
bar represents median and interquartile range
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Table 1 Baseline characteristics of all treated patients

their environment for hypoxia or other stress signals
and making use of multiple pathways, to respond more
accurately according to the physiological needs [43, 44].
Here, we demonstrate that skin-derived A
 BCB5+
MSCs adaptively activate the proangiogenic HIF-1
pathway in response to hypoxic conditions. Activation occurred through posttranslational stabilization
of HIF-1α protein (which at normoxia is subject to
rapid degradation), which resulted in cellular accumulation and translocation to the nucleus (Fig. 1A). HIF1α pathway response to hypoxia became also evident
at the transcriptional level, albeit with different kinetics: Whereas HIF-1α protein accumulation and nuclear
translocation was most pronounced at 24 h, HIF-1α
mRNA levels, after initial upregulation to peak levels
already at 1 h, progressively decreased during sustained
hypoxia, having returned to baseline levels at 5 h and
dropping further thereafter (Fig. 1B). Similar kinetics of
HIF-1α mRNA expression in response to hypoxia have
been observed in various cell types including endothelial cells and have been ascribed to a negative feedback
loop that counteracts excessive HIF-1α protein accumulation during prolonged hypoxic conditions [71].
Interestingly, in mice transplanted with subcutaneous
gel grafts cellularized with MSCs and endothelial progenitor cells (EPCs), genetic ablation or pharmacologic
inhibition of HIF-1α in the MSCs completely abrogated
experimental vessel formation in the gel graft, while
HIF-1α deletion in the EPCs had no effect on vasculogenesis [72]. Thus, even though HIF-1α pathway activation is basically a common mechanism by which a cell
adapts to reduced oxygen tension, HIF-1α stabilization
in MSCs was considered a crucial event in cell-based
therapeutic vasculogenesis [72]. In A
 BCB5+ MSCs,
HIF-1 pathway activation was accompanied by about
fourfold upregulation of VEGF transcription (Fig. 1C),
which eventually resulted in a substantial increase in
VEGF protein secretion (Fig. 1D).
In addition to paracrine VEGF secretion under hypoxic
conditions, ABCB5+ MSCs proved capable of adopting
phenotypic and functional characteristics of endothelial
cells in vitro, as demonstrated by expression of CD31
when cultured in growth factor-supplemented medium
(Fig. 2A) and formation of capillary-like structures similar to HUVECs when seeded on gel matrix (Fig. 3). This
suggests that A
 BCB5+ MSCs can trans-differentiate into
endothelial-lineage cells, and might imply that, beyond
serving paracrine proangiogenic functions to promote vascular regeneration, A
 BCB5+ MSCs could even
directly participate in neoangiogenesis in the injured
tissue. Previously, A
 BCB5+ MSCs have shown superior
homing and engraftment to mouse skin wounds as compared to bone marrow-derived MSCs [73]. Graft survival

Variable
Age, years

Full analysis set (N = 23)
Median (range) 62 (49–79)

Sex
Male

n (%)

20 (87)

Female

n (%)

3 (13)

Body weight, kg

Median (range) 105 (71–141)

Body mass index, kg/m2

Median (range) 33 (26–44)

Target wound surface area,
cm2

Median (range) 2.6 (1.0–15.2)

Ankle-brachial index

Median (range) 1.1 (0.8–2.0)

Hemoglobin A1c, %

Median (range) 7.2 (5.0–9.8)

Spearman’s rank correlation coefficient of 0.007 (95%
CI = − 0.429, 0.417; p = 0.97) indicated that there was no
association between these two parameters (Fig. 8C).
Safety outcomes

During the whole study period, 93 treatment-emergent adverse events (TEAEs) were reported in 20 of
23 patients (Table 3). Most TEAEs were mild or moderate; 3 TEAEs reported by two patients were severe.
Twelve TEAEs reported by 10 patients were serious
(Additional file 1: Table S12). None of the TEAEs was
judged related to the cell product.
During efficacy follow-up, no clinically relevant
changes in vital signs occurred (Additional file 1:
Table S13). Eighteen physical examination findings
that were either not present at baseline or had changed
versus baseline were documented in 10 patients (Additional file 1: Table S14). Of these, 10 findings (56%) represented improvements.

Discussion
Despite well-established strategies for DFU management, treatment is often challenging, and many patients
respond only poorly to standard treatment. Experimental approaches that directly target defective pathways
in the wound tissue, including blockade of IL-1β by a
neutralizing antibody or IL-1RA [30, 64, 65], stabilization of HIF-1α using prolyl hydroxylase inhibitors, iron
chelator or protein–protein interaction inhibitors [35,
37, 66, 67] or topical supplementation of pro-angiogenic growth factors [39, 68], have accelerated wound
healing in diabetic mice. However, the clinical translation of these approaches has been hampered by various hurdles including safety concerns, short half-lives
and/or the requirement of specific delivery systems [67,
69, 70]. In contrast to single-drug approaches, therapeutically applied MSCs are considered, by sensing
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Day 0
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Week 12

Fig. 6 Wound healing progress during the treatment and efficacy follow-up period. Shown are three representative patients in the subgroup of
responders. All patients had consented to publication of the photographs

was demonstrated in the skin against a fully allogeneic
barrier (BALB/c A
 BCB5+ MSCs administered to C57/
BL6 mice) for at least 17 days [51]. Moreover, in an NSG
mouse wound model, significant detection of humanspecific CD31 DNA in the wound tissue at 13 days after

topical application of human A
 BCB5+ MSCs has indicated that endothelial trans-differentiation of these cells
can actually occur in vivo [54]. Still, whether therapeutically applied ABCB5+ MSCs indeed become integrated
in the regenerating vasculature remains to be elucidated.
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Fig. 7 Wound surface area reduction in DFU patients treated with ABCB5+ MSCs. A–B Percent wound surface area reduction from baseline
during the treatment and efficacy follow-up period in the full analysis set (A) and per-protocol set (B). Patients who presented with wound surface
area reductions of at least 30% from baseline (indicated by light green dashed lines) at week 12 were considered responders. Error bars indicate
median and interquartile range; p values (two-sided Wilcoxon signed rank test) indicate statistical significance of changes from baseline. C Tukey’s
boxplots of the primary efficacy outcome parameter, % wound surface area reduction from baseline at week 12, in the full analysis set (FAS, N = 23),
per-protocol set (PP, N = 20) and responders (i.e., patients who presented with at least 30% wound surface area at week 12; N = 17). D-E Kaplan–
Meier plots for the time to full wound closure (D) and first 30% surface area reduction (E) in the FAS, PP and responders. Patients without event were
censored at the date of the last available wound surface area assessment (indicated by small vertical ticks). Vertical dashed lines indicate median
time to event (not reached for full wound closure)

To investigate the vascular regenerative potential of
ABCB5+ MSCs in vivo, we studied the effects of intramuscular cell injection on perfusion restoration in a
mouse HLI model. As required from a drug regulatory
perspective [74, 75], we did not use mouse A
 BCB5+

MSCs but tested the ATMP made of human A
 BCB5+
MSCs. Importantly in this regard, a significant body of
studies comparing regenerative and anti-inflammatory
effects of rodent and human MSCs in immunocompetent
rodent models have confirmed a comparable efficacy of
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Table 2 Summary of the main secondary efficacy outcomes
Parameter

Full analysis set
(N = 23)

Per-protocol set
(N = 20)

Sourcea

1.7 (0.3–2.8)

2.0 (0.9–2.9)

Additional file 1: Table S7

Absolute wound surface area reduction
Change from baseline at week 12 (cm2)b
Complete wound closure
Patients with complete closure at week 12, n (%)

6 (26)

6 (30)

Additional file 1: Table S8

Patients with complete closure at any time up to week 12, (%)

6 (26)

6 (30)

Additional file 1: Table S8

Time to complete closure, daysc

Not reached

Not reached

Figure 7D

≥ 30% wound surface area reduction

Patients with ≥ 30% reduction at week 12 (“Responders”), n (%)

17 (74)

17 (85)

Additional file 1: Table S8

19 (83)

18 (90)

Additional file 1: Table S8

Time to ≥ 30% reduction, daysc

27 (14; 30)

22 (14; 30)

Figure 7E

Patients with wounds reopened at week 12, n (%)

0 (0)

0 (0)

n.a

Patients with ≥ 30% reduction at any time up to week 12, n (%)

Reopening after complete wound closure
Exudation
Wounds with low exudation, n (%)
  Day 0

10 (44)

7 (35)

Additional file 1: Table S9

  Week 12

12 (52)

10 (50)

Additional file 1: Table S9

Wounds with moderate exudation, n (%)
  Day 0

11 (48)

11 (55)

Additional file 1: Table S9

  Week 12

10 (44)

9 (45)

Additional file 1: Table S9

Amputation at target leg
Patients with amputation, n (%)

1 (4)

1 (5)

n.a

Time to amputation, days

42

42

n.a

Pain scoreb
Day 0

1 (0–3)

n.a

Additional file 1: Table S10

Week 12

1 (0–2)

n.a

Additional file 1: Table S10

Quality of lifed
Dermatology Life Quality Indexb
  Day 0

6 (1–12)

n.a

Additional file 1: Table S11

  Week 12

4 (0–10)

n.a

Additional file 1: Table S11

n.a. not applicable
a

Detailed results are given in Additional file 1: Tables S7–S11

b

Median (interquartile range)

c

Median (95%-CI)

d
Due to space limitations, SF-36 subscale scores (which remained virtually unchanged during the efficacy follow-up) are not shown here but given in Additional file 1:
Table S11

The median percentage wound surface area reduction was already statistically significant (p < 0.001) at 2 weeks and, except for the week-6 assessment (which was,
however, missed by 4 patients), increased further over time (Fig. 7A, B)

(See figure on next page.)
Fig. 8 Assessment of potential influences of baseline patient characteristic, baseline wound size and wound surface area reduction during the
screening period on response to treatment. Baseline patient characteristics and baseline wound surface area in all treated patients, responders and
non-responders. A–B Comparisons of baseline patient characteristics (A) and of wound surface area reduction during screening and of wound
surface area at baseline (B) between all treated patients, responders and non-responders. Depicted are Tukey’s boxplots (except for gender ratio);
n = 23 (all patients; ankle-brachial index: n = 22), n = 17 (responders; ankle-brachial index: n = 16), n = 6 (non-responders). Kruskal–Wallis tests
followed by Dunn’s multiple comparisons revealed no statistically significant differences between groups (p > 0.999 for all comparisons except
for ankle-brachial index responders vs. non-responders: p = 0.697). C Spearman’s rank correlation analysis between wound surface area reduction
during screening and wound surface area reduction from baseline at week 12. *Asterisk denotes a patient whose screening period lasted 118 days,
as compared to 42–68 days (median 49 days) for the other patients
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Table 3 Adverse events (SAS)
Event

Number of events Number (%) of patients

Any adverse eventa

120

21 (91)

Any TEAE

93

20 (87)

Any serious TEAE

12

10 (43)

Any treatment-related
TEAE

0

0 (0)

Frequent TEAEs by MedDRA system organ classb
General disorders and administration site
conditions

3 (13)

  Edema peripheral

2 (9)

Infections and infestations

15 (65)

  Infected skin ulcer

6 (26)

  Localized infection

4 (17)

  Nasopharyngitis

4 (17)

  Wound infection

2 (9)

Injury, poisoning and procedural complica‑ 5 (22)
tions
  Ligament sprain

2 (9)

Metabolism and nutrition disorders

4 (17)

  Hyperglycemia

2 (9)

Musculoskeletal and connective tissue
disorders

4 (17)

  Arthralgia

2 (9)

  Back pain

2 (9)

  Pain in extremity

3 (13)

Skin and subcutaneous tissue disorders

11 (48)

  Blisters

6 (26)

  Skin ulcer

4 (17)

MedDRA Medical Dictionary for Regulatory Activities; TEAE Treatment-emergent
adverse event; SAS Safety analysis set (N = 23)
a

Includes pretreatment-emergent (occurring between giving written consent
and first cell application) and treatment-emergent (occurring between first cell
application and end of safety follow-up) adverse events

b

Only TEAEs that were reported by at least 2 patients

allogeneic and xenogeneic MSCs [76–78]. This has been
attributed to the low levels of HLA and co-stimulatory
molecules expressed by MSCs and by the fact that both,
allogeneic and xenogeneic MSCs, survive only for a limited time in the host, before species differences could
manifest [76]. In the HLI model, A
 BCB5+ MSCs markedly accelerated perfusion recovery as measured by LDPI
(Fig. 4B; Additional file 1: Table S5). At the microscopic
level, ABCB5+ MSCs significantly increased the vascularization assessed by CD31 immunostaining (Fig. 4C;
Additional file 1: Table S6) and enhanced the proliferation of capillaries in the ischemic muscles (Fig. 4D,F).
Beside proangiogenic capacity based on paracrine
activity and endothelial differentiation, a third principal
mode of action by which MSCs perform their effects over
injured tissue is through interaction with the immune
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system. While immune modulation has not been
addressed in the present study, previous studies have
demonstrated that A
 BCB5+ MSCs respond to inflammatory milieus through multiple cell contact-dependent
and paracrine mechanisms [51–53], including dampening the IL-1β-driven inflammation in chronic wounds by
adaptive IL-1RA release, thereby shifting the prevalence
of M1 toward proangiogenic and repair-promoting M2
macrophages in the wound tissue [53].
With respect to these three principal modes of actions
we have developed and established three potency assays
to guarantee biological functionality and predict clinical effectiveness of therapeutically applied A
BCB5+
MSCs: (i) VEGF secretion under hypoxic conditions to
evaluate the angiogenic potency, (ii) tube formation on
extracellular matrix gel to evaluate the endothelial transdifferentiation capacity, and (iii) IL-1RA secretion after
cocultivation with M1-polarized macrophages to evaluate the immunomodulatory potency (Additional file 1:
Table S4).
Based on the in vitro and preclinical observations, we
investigated ABCB5+ MSCs as a potential option for
adjunctive treatment of DFUs. In the patient population
studied, the greatest treatment success achieved over
the ≥ 6-week screening period (median 7 weeks) with
standard care alone was approximately 50% wound surface area reduction in 3 of 23 patients (of whom 1 patient
was even treated 118 days), while in about half of the
patients the ulcer enlarged (up to 175%) (Fig. 5C). Thus,
in line with current DFU treatment guidelines, which
recommend to consider adjunctive therapy options for
DFUs that did not achieve a 50% area reduction within
4 weeks [19–21] or failed to heal after 4–6 weeks [22] of
standard treatment, these ulcers had appeared refractory
to standard treatment, indicating an urgent need for an
advanced wound closure strategy [19–22, 79].
In this hard-to-heal population, adjunctive topical
application of ABCB5+ MSCs elicited statistically significant median wound surface area reductions from
baseline of 59% (FAS), 64% (PP) and 67% (subgroup
of responders) after 12 weeks. Acceleration of wound
healing started early, becoming statistically significant
(p < 0.001) already at 2 weeks (median wound surface area
reduction 31% for FAS and PP) (Fig. 7A, B), which indicates that as early as at 2 weeks about half of the patients
(48% of FAS and 56% of PP) had passed the predefined
threshold value of 30% wound surface area reduction that
was considered to classify them as responders (Fig. 7D).
At 4 weeks, the median wound surface area reduction
was 44% (FAS) and 48% (PP), and 1 patient (4% of FAS
and 5% of PP) presented already with full wound closure (Fig. 7A, B), which together revealed that the overall situation had clearly improved as compared to the
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standard-of-care screening period. Finally, at week 12,
6 of these urgent-need patients (26%, 30% and 35% of
FAS, PP and responders, respectively) had reached full
wound closure, and it seems reasonable to expect that
this rate would increase further if the follow-up period
was extended, as suggested by the observation that the
median wound surface area reduction was still increasing
(Fig. 7A, B).
A variety of other cell-based treatment strategies have
been tested in controlled clinical trials for adjunctive
treatment of DFUs, including autologous and allogeneic
MSCs derived from bone marrow and adipose tissue
[80–82], autologous adipose tissue and adipose-derived
stromal vascular fraction cells [83, 84], autologous platelet-rich plasma [83, 85–90], allogeneic platelets [91],
autologous skin cells [92], skin allografts [93], and various cell-containing skin substitute products [94–99] (for
a summary see Additional file 1: Table S15). The reported
effects show great variations, ranging from wound surface area reductions and full wound closure ratios within
12–26 weeks that did not significantly differ from the
control groups [82, 83, 85, 92] to impressive significant
wound surface area reductions from baseline of up to
98% within 80 days [90] and wound closure ratios of up
to 100% within 8 weeks [84]. However, in the trials that
observed superiority of the investigational treatment
over standard treatment, the reported outcomes in the
standard treatment (control) groups ranged up to 88%
wound surface area reduction [90] and 78% full wound
closure ratio [88], indicating that considerable proportions of the treated wounds have not been refractory to
standard treatment (Additional file 1: Table S15). In contrast, in the present trial we have focused on a standard
treatment-refractory, extremely hard-to-heal population,
which needs to be taken into account when comparing the outcomes in the present trial with those of other
adjunctive treatment strategies.
In view of the high personal and socioeconomic disease burden of DFUs it has become desirable to identify
the patients who are likely to benefit from an adjunctive
treatment strategy as early as possible. Basically, the phenomenon that a certain proportion of patients do not
respond to the treatment, is widely known across the
various MSC therapy approaches in a broad range of diseases, with non-responders potentially amounting up to
60% of the treated patients [100]. A major part of variability in clinical outcomes of MSC therapies has been
ascribed to heterogenous products with insufficiently
characterized therapeutic potency [49]. In contrast, in
the present study, the strongly standardized quality and
potency of the cell product (Additional file 1: Table S4)
rules out potential differences in quality and bioactivity
as a cause of variation in the treatment responses, which
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is supported by the comparably low non-responder rates
of 26% (FAS) and 15% (PP). Importantly, there was no
association between the treatment responses and the
potency assay data of the applied cells (Additional file 1:
Table S4), which indicates that the specified threshold
acceptance values for product release are strong enough
to guarantee proper biological activity. When comparing potential patient-related negative predictors for DFU
healing such as greater wound surface area [101–106]
and patient characteristics including older patient age
[106–108], male gender [104, 109], very high [110] or
very low [108] body mass index, lower ankle-brachial
index [109] and lower hemoglobin A1c [111], there were
no significant differences between the responders and the
non-responders that seem to have contributed to failure
of treatment response (Fig. 8A). Clearly, however, the
etiology of impaired DFU healing is far more multifactorial, involving, e.g., previous diabetes control, comorbidities, and psycho-social factors [79]. On a cellular level,
differential regulation or variations of genes involved in
skin barrier function, inflammation or vascularization
and blood flow have been associated with impaired DFU
healing [112–115]. To further investigate what segregates responders to ABCB5+ MSC treatment from nonresponders could aid identifying predictors of response
which might help distinguishing already before treatment
initiation the patients that will likely respond to ABCB5+
MSC therapy from those who will not.
Naturally, the conclusions drawn from the present trial
are limited by factors typically associated with earlyphase trials, particularly a small patient number and an
open, non-randomized design. Even though all ulcers
had emerged refractory to standard treatment, we cannot rule out that part of the observed improvements has
occurred through additional attention and care during
the trial. Not least, as discussed above, wound healing
can be influenced by various patient-specific factors that
were not controlled for.
Despite these limitations, we conclude that the present
results support GMP-manufactured dermal A
BCB5+
MSCs as a potential developable candidate for adjunctive therapy of standard treatment-refractory DFUs,
even though in the present trial the majority of responders achieved only partial wound closure. Clearly, partial
wound closure is a clinically less meaningful outcome
than full wound closure; however, it is considered valid to
“indicate relevant biological activity and help guide subsequent trials design” [75]. Importantly, the absence of any
treatment-related adverse event during the trial confirmed
good tolerability and overall safety of the cell product.
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Conclusions
The present studies demonstrate the in vitro and in vivo
angiogenic potential of ABCB5+ MSCs based on both,
paracrine pro-angiogenic factor secretion and trans-differentiation into endothelial-lineage cells. Together with
the wound surface area reduction observed upon topical administration onto chronic DFUs, the results support GMP-manufactured ABCB5+ MSCs as a safe, viable
candidate for adjunctive therapy of treatment-refractory
DFUs and warrant further investigation in a larger randomized controlled trial with a dose-ranging design, an
extended efficacy follow-up period and advanced outcome measures in order to validate the benefit and optimize the dose regime.
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